Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. - This study was undertaken to investigate the histologic outcomes with vedolizumab vs adalimumab in ulcerative colitis. Individuals in VARSITY were assigned randomly in a 1:1 to vedolizumab 300-mg intravenous infusions or adalimumab 40-mg subcutaneous injections. Researchers used Geboes and Robarts Histopathology Index (RHI) scores to evaluate prespecified histologic exploratory endpoints (histologic remission [Geboes < 2 or RHI ≤ 2] and minimal histologic disease activity [Geboes ≤ 3.1 or RHI ≤ 4]) at Weeks 14 and 52. A sum of 769 individuals received vedolizumab (n=383) or adalimumab (n=386). The results showed that in both anti-TNF–naïve and –failure subgroups, higher rates of histologic remission, minimal histologic disease activity, and combined histologic plus endoscopic outcomes were observed with vedolizumab vs adalimumab in ulcerative colitis.